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Stress factors
and medicinal products
Stability is defined as the extent to
which a product retains, within specified
limits, throughout its period of storage and
use, the same properties and characteristics
that it possessed at the time of its
manufacture. There are various stress factors
that can accelerate loss of stability. In view
What is an expiry date? Quite simply, it is an assurance that a
medicinal product will meet applicable standards of identity,
strength, quality and purity at the time of use.1 However, this
assurance is not all-encompassing; it is only applicable under
the storage conditions specified by the manufacturer on the
labelling and packaging following extensive stability studies.
Failure to provide for the storage conditions specified by
pharmaceutical manufacturers invalidates this assurance and
consequently, it is the responsibility of manufacturers,
distributors, importers and dispensing pharmacists to ensure
that adequate provisions are taken in their premises in this
regard throughout the shelf life of the product.
of the importance of chemical degradation
as a means of instability, and that
underlying chemical or physicochemical
mechanisms are often responsible for
physical instability, the major stress factor
is temperature, since increases in
temperature cause increases in the rate of
degradation of medicinal products. However,
it should not be assumed that it is merely
elevated temperatures that are detrimental
to a product’s stability. Excessively reduced
temperatures can also cause loss of
stability, such as by decreasing the
solubility of solutes in a given solvent,
while oscillations in temperatures can cause
a change in particle size in suspensions (the
Ostwald ripening effect), thus altering the
dissolution profile and possibility the
bioavailability of the product.
Labelling
of medicinal products
Given the importance of proper storage
of medicinal products, some attention
should be paid to the labelling of medicinal
products and the instructions given thereon.
The determination of the expiry date of a
medicinal product is a result of stability
studies under long term, accelerated and,
sometimes, intermediate conditions. The
selection of the combinations of
temperature and humidity are determined
by the climatic zone within which the
medicinal product is intended to be stored
and distributed. In the early years of a
product’s market life, its shelf life is
sometimes calculated by extrapolation of
stability study data through statistical
analysis. The availability of suitable data
allows a fairly accurate shelf life to be
determined. The situation is less certain
when, at the time of application for a
market authorization, the product has not
shown sufficient degradation, or indeed no
degradation, that will allow statistical
analysis of the kinetics of degradation to
generate a shelf life with a degree of
certainty. Under both these circumstances a
shelf life which is twice the length of the
long term stability study carried out to date
is allowed, up to a maximum of one year
beyond the data obtained in the long term
study.2 Ongoing stability studies are
subsequently undertaken post-marketing to
monitor the product and confirm the
validity of the labelled shelf life.3
Malta, being a Mediterranean country,
falls within Climatic Zone II (Table 1).
Unless other stress factors, such as relative
humidity (RH), light and microbiological
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contamination, have a more predominant
effect on shelf life, products intended for
storage in Climatic Zone II are tested
under accelerated conditions at 40oC ±
2oC, 75% RH ± 5% RH for a minimum of 6
months, and under long term conditions
at 25oC ± 2oC, 60% RH ± 5% RH for a
minimum of 12 months.4 The
manufacturer also has the option of
additional testing under intermediate
conditions of 30oC ± 2oC, 65% RH ± 5%
RH, or of carrying out the long term study
under these latter conditions rather than
those previously mentioned, particularly if
the product is intended for export to a
country in Climatic Zone III or IV.5 The
outcome of the stability study determines
the labelling requirements of the finished
product (Table 2). However, products that
suffer from stability issues at lower
temperatures will also bear statements to
this effect (“Do not refrigerate or
freeze”).6
Good practice in the storage
of medicinal products
The European Commission’s Guide to
Good Manufacturing Practice, with regards
to storage areas, states that “Storage
areas should be designed or adapted to
ensure good storage conditions. In
particular, they should be clean and dry
and maintained within acceptable
temperature limits. Where special storage
conditions are required (e.g. temperature,
humidity) these should be provided,
checked and monitored.”.7 Similar
provisions are also listed in the
Commission’s Guidelines on Good
Distribution Practice: “Medicinal products
should normally be stored apart from
other goods and under the conditions
specified by the manufacturer in order to
avoid any deterioration by light, moisture or
temperature. Temperature should be
monitored and recorded periodically.
Records of temperature should be reviewed
regularly.”.8
In the case of medicinal products which
do not require special storage conditions
(i.e. refrigeration or freezing), these two
concise statements are based on the need
to store medicinal products under
conditions of controlled temperature
without compromise to their stability and
shelf life. The word “controlled” implies a
degree of control over the temperature of
the environment, such that extremes of hot
and cold temperature are not encountered.
This, in turn, also implies the need for some
degree of periodic temperature monitoring
using one or more appropriately-located,
calibrated devices.
Application of good practice
to community pharmacies
Based on meteorological data for 2004,9
Malta’s mean kinetic temperature was
20.3oC, with the lowest mean minimum
temperature being registered in January
(9.4oC) and the highest mean maximum
temperature in July (31.0oC). Such ranges in
temperature, whilst not excessive, are
certainly not consistent with the concept of
a controlled temperature environment, and
therefore the installation of an air-
conditioning unit to cool or warm the
pharmacy is necessary. Most, if not all,
pharmacies in Malta are already equipped
with such a unit. However, one’s faith in the
ability of the unit to control the
temperature in the desired location/s
should not be a blind one. It should not be
assumed that, merely because the remote
control reads 20oC, the unit’s thermostat is
also accurately set to 20oC, neither that the
unit is effectively maintaining a
temperature of 20oC in all areas of the
pharmacy. It is therefore recommendable to
engage in a few simple good practice
measures in this regard.
• Purchase one or two min-max
thermometers. How many you need
depends on the size and layout of the
pharmacy. There are mercury-in-glass,
ethanol and electronic types: choose one
which you can read and reset quickly,
easily, and with a minimum of fiddling
about with various buttons.
• Have the accuracy of the thermometers
checked for you at least once a year,
either by the supplier or the local
standards authority. If your thermometer
is not accurate to within 1-2oC, you
should consider replacing it. You should
also request a certificate confirming the
results of the validation and indicating
the next validation date.
• Carry out some elementary temperature
mapping to see whether the average
temperatures of different areas of the
pharmacy are the same. If you have a
long dispensing counter, you might find
that temperatures are different at the two
ends of the counter, particularly if one
end is close to the entrance. The same
applies if you have some medicines
behind the counter, and a stock of
medicinal products in a separate store
room or dispensing room, especially if air
exchange between the two areas is
limited or ineffective. If the two areas do
not maintain similar temperatures (within
1-2oC of each other), install two
thermometers, one in either location. Do
not keep one thermometer, shuttling it
between the two locations; it will
completely defeat the purpose of min-
Climatic Condition Zone I Zone II Mediterranean Zone III  Hot/dry Zone IV
Temperate (sub-tropical)  or Hot/moderate RH  Very hot/humid
Mean Annual Temperature <20oC 20.5 - 24oC >24oC >24oC
Kinetic Mean Temperature 21oC 26oC 31oC 31oC
Mean Annual Relative  Humidity 45% 60% 40% 70%
Table 1: International Climatic Zones and Climatic Conditions10
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max monitoring over a period of time and
the possibility of adversely affecting the
thermometer’s accuracy will increase.
• Install the thermometers in a convenient
place to read (avoid having to climb on a
stool each time). Make sure the location
of the thermometer is a valid one, that is,
as close to the medicinal products as
possible.
• Monitor the maximum and minimum
temperatures at least once weekly, and
reset the thermometers. Log your
readings: if you don’t keep a record that
you did it, then you didn’t do it!
• Analyse the data by calculating the
monthly mean kinetic temperature. The
mean kinetic temperature is that single
(derived) temperature that, if maintained
over a period of time, would provide the
same thermal challenge to a drug product
as would be experienced due to a range of
both higher and lower temperatures for
that same time period. It normally has a
higher value than the arithmetic mean
temperature and takes into account the
Arrhenius equation for temperature
dependence of reaction rate constants.4
An example of a calculation of the mean
kinetic temperature is shown in Table 3.
It can be seen that, provided the number
of temperature excursions outside the 20-
25oC range is small, the effect on the
chemical stability of the compound is
equivalent to a constant temperature
maintained within range. Check that the
mean kinetic temperature falls within the
desired range, namely 20-25oC, but also
that the number of raw data temperature
excursions outside this range is limited to
an acceptably small number (no more
than once or twice monthly).
What if your mean kinetic temperature
falls just outside the 20-25oC or the number
of temperature excursions outside this limit
is excessive? In most cases, the situation
may be brought under control by simple
measures aimed at controlling air flow in
the pharmacy, thus increasing the
effectiveness of your air-conditioning unit/
s.
• Keep the door to the street closed as
much as possible; an open door causes
exchange of air between the street and
the pharmacy, decreasing the
effectiveness of your temperature control.
• If the medicines in your dispensing area are
behind some form of partition, keep the
partitions closed during opening hours,
particularly in the summer months; this will
reduce exchange of slightly warmer air from
the pharmacy with the medicines; the same
applies if you have a separate dispensing or
store area.
• Try and promote air exchange between
cooler and warmer parts of the pharmacy,
especially if your air-conditioner is “over-
effective” in one region and “under-
effective” in another. This can be done by
the use of a strategically located fan.
Monitor the temperatures to see if your
efforts are successful.
• Remember that temperature control applies
also at night and on Sundays and public
holidays; failure to do so will generate
numerous temperature excursions from the
required range. Try and exchange the remote
control of your air conditioner for one which
will allow you to program the unit to turn on
and off at awkward times if this feature is
not currently available. The judicious use of
the air conditioner at key moments in the
day or night will give a more effective
temperature control than leaving the unit on
or off indiscriminately. Moreover, this will
reduce electricity consumption and increase
the life of your unit.
• If one part of your pharmacy appears to
have a slightly higher mean temperature
which you cannot lower, then stock your
medicines accordingly: place those with a
“Do not store above 25oC” or “Do not store
above 30oC” in the region of the pharmacy
with better temperature control, and those
with no particular storage requirements in
the area with poorer control.
Testing conditions Required labelling statement
where stability has been shown
25oC / 60% RH (long term) and None
40oC / 75% RH (accelerated)
30oC / 65% RH (long term) and None
40oC / 75% RH (accelerated)
25oC / 60% RH (long term) and Do not store above 30oC or
30oC / 65% RH (intermediate) Store below 30oC
30oC / 65% RH (long term) Do not store above 30oC or
Store below 30oC
25oC / 60% RH (long term) Do not store above 25oC or
Store below 25oC
25oC / 60% RH (long term) Do not store above 25oC or
Store below 25oC
Table 2: Storage Statements on the Medicinal Product Label6
Practice Points
• Purchase one or more min-max thermometers.
• Have the thermometers checked and certified regularly.
• Carry out temperature mapping.
• Install the thermometers in a convenient, valid location.
• Monitor the minimum and maximum thermometers weekly and log the data.
• Analyse the data by calculating the mean kinetic temperature.
• Manage the air flow in the pharmacy to obtain effective
temperature control.
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Advice to the patient
Finally, remember to advise the patient
as regards appropriate storage of medicinal
products. The entire objective of all these
measures is to guarantee the quality of the
medicinal product when administered to the
patient, who should in turn be encouraged
to store medicinal products in a cool place.
Nevertheless, the occasional patient will
admit to having left medicinal products in a
sunny place and will ask if the product is
still effective. A fairly good rule of thumb is
to remember that a 10o rise in temperature
approximately doubles the rate of most
reactions. Ultimately, however, the best
advice to give stems from the pharmacist’s
professional common sense, taking into
account the time of year, the duration of
exposure and the medicinal product under
consideration.
–ln
– 273.16
Week Minimum Maximum Average Average e -9982.68/T
(oC) (oC) (oC) (Kelvin)
1 20 24 22.0 295.16 2.05x10-15
2 23 27 25.0 298.16 2.88x10-15
3 19 23 21.0 294.16 1.83x10-15
4 21  24 22.5 295.66 2.17x10-15
T is the recorded temperature in Kelvin (oC + 273.16), n is the number of readings,
ln represents natural logarithms, and e is the natural logarithm base.
e-9982.68/T  =  2.05x10-15 + 2.88x10-15 + 1.83x10-15 + 2.17x10-15  =  8.93x10-15
9982.68
8.93 x 10-15
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Mean Kinetic Temperature =
 n
Σ
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-ln
– 273.16 = 22.7oCMean Kinetic Temperature =
Table 3: Calculation of the Mean Kinetic Temperature11
